Characterization of Early Markers of Choroidal Neovascularization (CNV-Markers)
|ClinicalTrials.gov Identifier: NCT00801541|
Recruitment Status : Completed
First Posted : December 3, 2008
Last Update Posted : March 19, 2015
|Condition or disease|
|Age-related Macular Degeneration|
The primary statistical objective of this study is to identify the sequence of alterations occurring in the chorioretinal interface during progression of AMD from risk "dry" AMD to sight-threatening chorioretinal neovascularization (CNV) (wet AMD).
Different imaging methods will be used simultaneously and at regular intervals in order to characterize markers or predictors of conversion to sight-threatening CNV will be: CNV (classic or occult) or position of CNV within 2500 µm (~1.7 disc diameters) of the foveal center, as evidenced by fluorescein angiography.
This is an institutional, prospective, observation study to be performed in fellow eyes of patients with evidence of "wet" AMD in other eye. Therefore, patients will have evidence of exudative ("wet") AMD in one eye ( the non-study eye) and non-exudative ("dry") AMD in the fellow eye (the study eye) that is at risk for progressive to exudation "wet" CNV.
Patients will exit the study at the time of developing sight-threatening CNV in the study eye and will be treated at the discretion of the physician.
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||Characterization of Early Markers of Choroidal Neovascularization in Fellow Eyes of Patients With AMD and CNV in One Eye. (CNV-Markers)|
|Study Start Date :||December 2005|
|Primary Completion Date :||December 2008|
|Study Completion Date :||June 2014|
Patients with wet AMD in one eye and dry AMD in the other eye (study eye).
- Wet AMD development in the study eye. [ Time Frame: Single Visit ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801541
|AIBILI - Clinical Trial Center|
|Coimbra, Portugal, 3000-548|
|Principal Investigator:||José Cunha-Vaz, MD PhD||Association for Innovation and Biomedical Research on Light and Image|